Specify Company / Ticker to Get the Summary
Dividend History OPTN
Dividend Analytics OPTN
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–OptiNose
OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc. Address: 777 Township Line Road, Yardley, PA, United States, 19067
Analytics
WallStreet Target Price
21.00 USDP/E Ratio
–Dividend Yield
–Financials OPTN
Results | 2019 | Dynamics |